Phoenix Financial Ltd. acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 3,608 shares of the biotechnology company's stock, valued at approximately $552,000.
A number of other large investors also recently bought and sold shares of the stock. Lee Danner & Bass Inc. acquired a new stake in shares of Biogen in the 4th quarter valued at $25,000. Larson Financial Group LLC grew its holdings in Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 141 shares during the last quarter. SRS Capital Advisors Inc. purchased a new stake in shares of Biogen in the fourth quarter valued at about $33,000. OFI Invest Asset Management purchased a new stake in shares of Biogen in the fourth quarter valued at $32,000. Finally, Golden State Wealth Management LLC acquired a new stake in Biogen in the 4th quarter worth about $41,000. Institutional investors and hedge funds own 87.93% of the company's stock.
Biogen Trading Up 0.2 %
NASDAQ:BIIB traded up $0.25 during trading hours on Wednesday, hitting $117.23. The company had a trading volume of 411,684 shares, compared to its average volume of 1,633,642. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $238.00. The company has a market capitalization of $17.16 billion, a PE ratio of 10.48, a price-to-earnings-growth ratio of 1.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The stock has a 50-day moving average price of $135.71 and a 200 day moving average price of $152.96.
Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. On average, equities research analysts predict that Biogen Inc. will post 15.83 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have issued reports on the stock. Canaccord Genuity Group dropped their price objective on shares of Biogen from $298.00 to $265.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. William Blair reaffirmed an "outperform" rating on shares of Biogen in a report on Monday, January 13th. Truist Financial dropped their price target on shares of Biogen from $220.00 to $210.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. StockNews.com downgraded shares of Biogen from a "strong-buy" rating to a "buy" rating in a report on Saturday, December 28th. Finally, Needham & Company LLC restated a "hold" rating on shares of Biogen in a research report on Wednesday. Eighteen research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, Biogen has an average rating of "Hold" and a consensus price target of $213.15.
Read Our Latest Analysis on Biogen
Insider Buying and Selling at Biogen
In related news, Director Stephen A. Sherwin sold 8,760 shares of Biogen stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares in the company, valued at $1,697,926.36. The trade was a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.
Biogen Company Profile
(
Free Report)
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
Read More
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
